Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. by Wilson, M. S. et al.
Br. J. Cancer (1993), 68, 501 506 Macmillan Press Ltd., 1993~~~~~~~~~~~~-
Intra-tumoral heterogeneity of tumour potential doubling times (T0t) in
colorectal cancer
M.S. Wilson', C.M.L. West4, G.D. Wilson6, S.A. Roberts5, R.D. James2 & P.F. Schofield3
'Tumour Biochemistry Laboratory, Clinical Research Department; Departments of2Radiotherapy and'Surgery, Christie Hospital
NHS Trust, Manchester M20 9BX; 4Cancer Research Campaign Departments ofExperimental Radiation Oncology and
5Biomathematics and Computing, Paterson Institutefor Cancer Research, Manchester M20 9BX; 6CRC Gray Laboratory, Mount
Vernon Hospital, PO Box 100, Northwood, Middlesex, UK.
Summary Intra-tumoural heterogeneity of proliferation has been assessed by taking multiple biopsies from 30
colorectal cancers. Following in vivo IUDR labelling, dual parameter flow cytometry was used to measure
tumour DNA index (DI) and labelling index (LI) and to derive DNA synthesis time (Ts) and potential
doubling time (Tpo0). Heterogeneity was seen for all parameters under investigation. Overall coefficients of
variation (CV) and logarithmic transformation of T, and Tpo, (due to their non-gaussian distributions) indicate
that LI (CV 25%) was the most variable parameter. Intra-tumoral heterogeneity in Tpot (InTp,, CV = 22%) was
less than inter-individual variation (CV= 63%), suggesting that this variation should not be a limitation to the
possible usefulness of this technique as an indepednent prognostic indicator. Correlations of Tpo, values were
examined between the shortest, the median and the value for a pooled homogenate sample from a single
tumour. Using an homogenate, it was possible to accurately predict classification of tumour Tp,> values as
being below the median ('fast tumours') in 15 of 19 cases (79%). The data suggest that assaying an
homogenate may allow a more rapid analysis of a multiply sampled tumour.
Colorectal cancer is a common malignancy which carries the
same threat to survival now as it did 30 years ago. There is
some evidence that adjuvant chemo- or radiotherapy may
improve local recurrence rates and survival (Laurie et al.,
1989; Jones et al., 1989; Metzger, 1991). The ability to
accurately detect patients who may need and respond
favourably to additional treatment would be an advantage
and would increase the likelihood of determining potential
benefits of adjuvant therapy. The measurement of tumour
proliferation may help in the identification of tumours which,
because of their rapidly proliferative nature, might benefit
from modification of their radiotherapy (Dische & Saunder,
1989); and secondly may be more susceptible to chemo-
therapy than less proliferative lesions (Riccardi et al.,
1991).
The measurement of tumour potential doubling time (Tp,,)
using in vivo bromodeoxyuridine (BUdR) or iododeoxy-
uridine (IUdR) and dual parameter flow cytometry can be
performed on pre-operative biopsies (Begg et al., 1985).
Previous studies have indicated that this technique will yield
results on pieces of tissue of less than 100 mg (Wilson &
McNally, 1991). No relationship has been shown between
proliferation measured in this way and tumour stage or grade
(Dische et al., 1989; Rew et al., 1991, 1992), whilst values for
Tpot have been reported to be independent of age, sex and
tumour site or size (Wilson, 1991). These findings suggest
that Tp,t may be independent of prognostic value. The
validity of this measurement, however, would depend to a
degree on the extent of heterogeneity present within a
tumour, the amount of which would dictate the number of
biopsies required to obtain a reliable impression of the most
proliferative or dominant cellular sub-population of the
tumour.
It is well established that colorectal cancer is a
heterogeneous tumour. For example, this has previously been
demonstrated with respect to tumour DNA content (Scott et
al., 1987; Koha et al., 1990; Wersto et al., 1991; Hiddemann
et al., 1986), S phase fraction (Lindmark et al., 1991; Kouri
et al., 1990), and expression of Ki67, a marker of prolifera-
tion (Shepherd et al., 1988). In this study the degree of
intra-tumoral heterogeneity present in tumour DNA content,
expressed as the DNA index (DI) and IUdR related flow
cytometric parameters (labelling index, LI; DNA synthesis
time, T7; and Tp,,) have been assessed.
Materials and methods
Samples
Thirty patients with proven colorectal adenocarcinomas were
given 200 mg of IUdR (Boehringher Mannheim) as an intra-
venous bolus with hospital Ethical Committee approval and
full informed consent. After 4-14.7 h (mean 8.1 ± 2.9 h) ran-
dom biopsies were taken from the resected surgical specimen
and the time (t) was recorded between the administration of
the IUdR and the removal of the surgical specimen from the
individual patients. All of the patients were treated by
surgery with none receiving prior chemo- or radiotherapy.
Twenty-seven tumours had six biopsies taken, two tumours
had five biopsies and one tumour had two biopsies taken.
Randomisation of multiple specimens was achieved by samp-
ling from completely separate parts of obvious tumour in a
clockwise direction. All samples were of analysable quality
except for three samples from two tumours, both of which
were from the 27 tumours biopsied six times. The biopsy
specimens were immediately placed into 70% ethanol at 4°C
in the operating theatre. Parallel samples were fixed in for-
malin for histopathological assessment. In 26 tumours, a
pooled 'homogenate' sample was prepared from each of the
multiple samples. This consisted of equal portions from all
six biopsies taken from each patient. Each sample was
thoroughly minced and mixed before preparation for flow
cytometry.
IUdRIDNA staining procedure
The method of sample preparation and analysis has been
described in detail elsewhere (Wilson & McNally, 1991; Wil-
son et al., 1988). In summary, on the day of analysis the
specimens were minced, then digested using 0.4 mg ml-' pep-
sin in 0.1 M HCI and the DNA partially denatured using 2 M
HCI for 15 min to expose the IUdR-incorporated DNA. Ap-
proximately 2 x 106 nuclei were incubated with a 1 in 20
dilution of anti-IUdR monoclonal antibody (Becton-
Dickinson) for I h hour at room temperature. After washing,
the nuclei were incubated with a 1 in 40 dilution of rabbit
anti-mouse IgG FITC conjugate (Dakopatts) for a further
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30 min. Finally, the nuclei were counterstained with pro-
pidium iodide (Sigma) at a concentration of 10ligml-' to
allow measurement of the total DNA content.
Data analysis
All the samples were analysed using an Ortho Systems 50H
Cytofluorograph (Becton-Dickinson) with 1024 channels. The
data analysis was performed in list mode by a single
observer. Measurements were made of tumour ploidy (DI),
labelling index (LI) and relative movement (RM), allowing
calculation of tumour DNA synthesis time (Ts) and the
potential doubling time of the tumour (Tpo,) as previously
described (Begg et al., 1985). Tpo, was calculated from:
T
Tpo = 0.8 xLI (1)
where 0.8 was the value assigned to A, a factor which
accounted for the variation in the age structure of the cells
(Steel, 1977). Ts was derived by:
1.0 - 0.5
s RM - 0.5 (2)
where t was the time period in hours between injection of
IUdR and tumour biopsy and RM was the 'relative
movement' of the labelled nuclei through the cell cycle. This
was calculated by subtracting the mean DNA content of the
G, population from that obtained for the IUDR labelled
nuclei and dividing it by the mean DNA content of the G,
subtracted from the mean of the G2 x M cells as follows
RM- FL(IUdR) - FLG, (3)
FLGI+M - FLGI
where FL(IUdR) is the mean red fluorescence of the green
labelled cells and FLGJ and FLG2+M are the mean red
fluorescence values of G, and G2 + M cells, respectively.
Statistical analysis
Spearman's rank correlation coefficients (r) and paired t-tests
were used to compare sets of parameters measured on the
same samples of tumours. One way analysis of variance was
used to determine the overall coefficients of variation (CV).
Mean CVs are provided for comparative purposes. These
were computed as a single average of the CV values for
individual tumours and as such take no account of the
different numbers of samples assessed. Ln(Tp7,) and In(Ts)
were used in preference to the untransformed values as this
gave a more normal distribution. A significance level of 0.05
was used throughout.
Results
Clinical details
Table I lists the classification of the 30 tumours with regards
to tumour position, stage and histological differentiation.
Tumour DNA content (DI)
Fourteen (47%) of the tumours were diploid and 16 tumours
had aneuploid populations. Twelve of the latter were wholly
aneuploid but in four there was a mixed population of both
diploid and aneuploid cells. In these four tumours, two
tumours had four of six biopsies which were diploid, one had
three diploid biopsies out of six and one had two diploid
biopsies out of six. Three of the four tumours had
homogenate samples prepared; one of which was diploid. In
this latter tumour, four out of the six biopsies were diploid.
In the 12 tumours that were wholly aneuploid, the coefficient
of variation (CV) of the DI ranged from two to 21%, the
overall CV was 6%.
IUdR relatedparameters
Figure 1 displays the data in order of ascending median Tp0,
value obtained for the 30 patients from whom multiple
tumour samples were taken and analysed in this study. A
wide range of Tpo> values existed between different individuals
(range of medians 1.5-12.35 days). Figure 2 illustrates the
Table I Clinical details
Tumour position
Rectum
Sigmoid
Transverse colon
Caecum
Recurrences Small bowl
Colonic
Tumour stage
Dukes' A
B
C
'D')
Recurrent tumours
Histological differentiation
Well
Moderate
Poor
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Figure 1 The individual Tpo, values from each of the 30 tumours are plotted in ascending order of the median values. The values
for the homogenate samples, individual tumour medians and the overall median value are also shown. Twenty-six tumours had six
samples and an homogenate taken, one had six biopsies only taken (19), two tumours were biopsied five times (18,21) and one
twice (20). In some cases fewer points are plotted due to the overlap of data.
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Table 11 Comparison of inter- and intra-tumoral variation using overall CVs (%) for 26
tumours biopsied six times and four tumours 2 4 times
Number of In In
HeterogeneitH tumours LI RM T, (T) T (T,j
Inter-tumoral 30 96.3 21.0 85.9 29.0 119.7 63.0
Intra-tumoral 30 27.6 7.3 35.7 9.0 63.2 21.9
Table III Comparison of mean intra-tumoral
this and other studies
variations between
Number of Mean CV (0%)
tunmours LI T, Tpo
Present study 30 25 26 35
Begg et al. (1988) 12 25 10 27
Van Oostrum et al. (1990) 6 16 11 21
Bennett et al. (1992) 8 27 15 30
Rew et al. (1992) 5 30 16 31
histograms of the distribution of the various IUdR related
parameters (LI, RM, T, and Tp,,,) and shows that LI and RM
had approximately normal distributions. The non-gaussian
distribution of T, and Tp,, indicated that logarithmic transfor-
mations of the data were more appropriate for these two
parameters. In all of the parameters the heterogeneity within
a tumour (intra-tumoral) was less than the heterogeneity
between tumours (inter-tumoral) (Table II). Results are given
for both linear and logarithmic values for T, and TP,. These
are provided to allow comparison with published values from
other studies where, to date, only linear data have been used
(Table III). Furthermore, in these studies the individual CVs
were averaged to provide a mean value and these have been
compared with the present study in Table III. However, it is
more appropriate to calculate overall CVs (to avoid over-
weighting smaller groups) in order to summarise variation
from a number of individual tumours. Using logarithmic
transformation and overall CVs, the greatest intra-tumoral
variation was seen in LI. In the four tumours where both
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diploid and aneuploid populations were detected, there was
no difference in the Tp,, values between the diploid and
aneuploid samples (patients 3, 10, 19, 29 in Figure 1).
Honmogeniate samiiples
Figure 3 shows the comparison between the pooled
homogenate T,,, values and the values obtained for the
median and the shortest TPO, value for 26 tumours from
which six biopsies were taken. The homogenate T,,, values
were significantly correlated with both the median values
(r = 0.69, P<0.001) and the shortest value obtained from the
tumour (r = 0.75, P<0.001). Direct comparison of the values
demonstrated that the actual value of the homogenates
generally fell below the median, but above the shortest value
of the random samples. The homogenate value was
significantly different from both the median (paired t test,
P= 0.04) and the shortest Tp(,, value obtained from the
tumour (paired t test, P<0.001). In one of the three tumours
where there were both diploid and aneuploid tumour popula-
tions, the homogenate sample did not detect the aneu-
ploidy.
Discussion
A rapid tumour growth rate is thought to be associated with
poor prognosis. The rate of tumour cell proliferation has
been demonstrated to be a major factor determining the
success of fractionated radiotherapy (Withers et al., 1988).
Tumour proliferation kinetics have been shown also to be
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Figure 3 The relationship between the homogenate Tpo, value
and a, the median value and b, the shortest value.
prognostic indicators for the surgical and chemotherapeutic
treatment of several types of cancer (e.g. Tubiana & Courdi,
1989; Alama et al., 1992). Measurements of thymidine label-
ling index as used in these studies are, however, time con-
suming. The flow cytometric method used in this work over-
comes this problem and can provide results within 24h of
tumour biopsy which have been shown to correlate well with
thymidine labelling (Hoshino et al., 1985; Wilson et al.,
1985).
The significance of any sample determination of Tpo,may
be devalued because of heterogeneity within a tumour. One
aspect of tumour heterogeneity will involve the precision in
the measurement of the various parameters. The degree of
machine reproducibility has been tested by re-analysing
nuclei from 30 specimens stored for 1 week at 4°C in the
dark. There were no significant differences in the measured
values obtained (Wilson et al., 1993). The errors due to
re-processing 51 specimens (different parts of the same
biopsy) have been evaluated also. In a global analysis of
variance (Wilson et al., 1993) intra-tumour heterogeneity has
been shown to be significant over and above the assay and
re-processing variability with a P<0.01 for the parameter
1pot.
Diversity within colorectal tumours has been demonstrated
in terms of morphology and differentiation (Zamcheck et al.,
1975; Leibowitz et al., 1976), the distribution and expression
of tumour associated proteins (O'Brien et al., 1981; Goslin et
al., 1981; Rognum et al., 1982; Gold et al., 1983), the in vitro
sensitivity to cytostatic drugs (Trope & Hakansson, 1975;
Siracky, 1979), in vitro growth characteristics (Dexter et al.,
1981; Kimball & Brattain, 1980) and in the kinetics of the
tumours as demonstrated by the measurement of S phase
fraction (Lindmark et al., 1991; Kouri et al., 1990) and Ki67
labelling (Shepherd et al., 1988) and the presence of multiple
DNA stemlines measured by flow cytometry (Hiddemann et
al., 1986).
In the present study, there was little evidence for multiple
aneuploid populations as the overall CV for the DI in the
aneuploid tumours was 6%, this is much less heterogeneity
than seen by Hiddeman et al. (1986) where 29 of 88 colorec-
tal tumours were identified with multiple aneuploid DNA
stemlines. However, four of the 30 tumours had both diploid
and aneuploid tumour populations. This would suggest the
need for multiple sampling in order to accurately assess the
ploidy status of the tumour. Jones et al. (1988) demonstrated
that if analysis had been limited to only one block ofcolorec-
tal tumour, the 'correct' ploidy status would have been deter-
mined in 75% of cases. This is similar to other studies on
colorectal tumours where correct ploidy determination would
have occurred in 72% and 77% (Quirke et al., 1987; Rew et
al., 1991). The present study demonstrates ploidy determina-
tion would have been correct in 26 out of 30 tumours
(87%).
It is likely that multiple sampling is required with regard to
the measurement ofIUdR related parameters ofproliferation
(LI, T1 and Tp,,). The present study indicates that there is
significant variation within individual tumours in all of these
parameters. The degree of intra-tumoral variation in Tp0,
measured as a mean CV (30%) is very similar to previous
studies on cervical cancer xenografts (Van Oostrum et al.,
1990), primary human bladder and head and neck tumours
(Begg et al., 1988; Bennett et al., 1992) and breast car-
cinomas (Rew et al., 1992). Although there is a significant
degree of intra-tumoral heterogeneity (ln(TpO,) CV 22%), it
compares favourably with the amount of inter-tumoral varia-
tion present (ln(Tp,01) CV 63%), indicating the ability to iden-
tify individual tumour proliferation characteristics (Table
II).
Other studies have suggested that LI is the most variable
factor involved in the production of Tpo, (Table III). If the
mean CV is taken as comparison, it would appear that in the
present study both LI and T1 are equally variable (both
23%). This may be related to the number of biopsies taken
from each tumour and the number of individual tumours
sampled; in the present study 27 of the 30 tumours (90%)
had six random biopsies taken, while Begg et al. (1988) took
a mean of 4.3 biopsies (range 2-10) from 12 tumours, Van
Oostrum et al. (1990) sampled six different xenograft
tumours, whilst both Bennett et al. (1992) and Rew et al.
(1992) took a mean of six samples from eight and five
individual tumours respectively. Although intra-tumour
heterogeneity has been examined on 62 colorectal tumours
(Rew et al., 1991), 60% of the tumours were sampled by only
two or three times and insufficient data were supplied to
calculate the variances. A more accurate measure of variance
is the overall CV. This value in combination with the natural
log of T7 and Tp,,, (due to their non-gaussian distributions)
reveals that LI is the most variable parameter in the present
study also.
Cell suspensions enzymatically prepared from tumours
may contain significant numbers of normal host cells with
values ranging from 15 to 90% of the total (Davidson et al.,
1992). A possible criticism of measuring proliferation on
tumour cell suspensions is the potential confounding
influence of not only host cell infiltrate but also the normal
mucosal or stromal cells present. However, it would be
unlikely that the diploid populations were in fact non-tumour
cells because of the degree of proliferation present within
these sub-populations. During this study a number of sam-
ples of normal colonic mucosa were analysed. These samples
had low LIs (<1.5%) and Tp,,, values that were greater than
30 days. Aneuploid tumours reportedly have higher LI and
shorter Tpo,values than diploid tumours (Rew et al., 1991),
suggesting a higher level of proliferation. In this study, how-
ever, those tumours with both diploid and aneuploid popula-
-T
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tions detected did not show any difference in proliferation as
far as Tp,o values were concerned. Furthermore, there was no
significant difference between the total LI in the aneuploid
tumours (i.e: the labelling index of all the nuclei, not just the
aneuploid ones) and the LI of the diploid tumours (mean LI
values 11.1% and 10.7% respectively, P= 0.61). This
paradox may suggest that the relationship between the pro-
liferation rate of different clones within a tumour is complex
and that the progression from diploidy to aneuploidy is not
associated with a proliferative advantage. It provides further
support for Tpo, as a useful parameter which may provide
additional, independent information about a tumour's
behaviour.
Tumours have been divided into slow or fast proliferators
on the basis of their relationship to the median value of Tp0,
(Begg et al., 1990). Whilst this does seem to provide some
degree of discrimination of tumours that will fare better with
hyperfractionated radiotherapy, the present study indicates
that if only a single biopsy is performed in colorectal
tumours, it would be possible to place individuals into the
wrong group (Figure 1). Twenty of the 30 tumours had
samples whose Tp0, values were both above and below the
overall median value. An homogenate sample might give an
accurate overall impression of the tumour's proliferative
nature. This would allow analysis of a single pooled sample
from a tumour which had been sampled in a multiple man-
ner. It has been suggested that either measuring several small
pieces independently or obtaining and processing as large a
piece as possible at one time by cutting it into small pieces
before adding the pepsin should provide similar mean
parameter values (Begg et al., 1988).
In this study, there were significant differences between the
homogenate and the median or shortest Tp0, values (P = 0.04
and <0.001 respectively), but there were good correlations
between the homogenate and either the median (r = 0.69) or
the shortest (r = 0.75) Tp,,, values. Furthermore, the
homogenate sample provided a Tpot value below the median
in 15 of 19 tumours which had samples above and below the
median; therefore 79% of tumours where an homogenate was
prepared would be correctly designated as 'fast' proliferators.
Five tumours had homogenate Tp0, values which were shorter
and one tumour had a value which was longer than any of
the individual values. This probably reflects heterogeneity
within the individual biopsies. Two separate parts of each
biopsy were taken. One was used to obtain the biopsy Tp,,
value and the other was pooled with other multiple samples,
disaggregated and then processed to give the homogenate
data.
In conclusion, because of the degree of intra-tumoral
heterogeneity, this study would support the need for multiple
sampling in order to correctly measure not only ploidy but
also the proliferation of colorectal tumours. Secondly, the
data suggest that the analysis of an homogenate may allow a
more rapid analysis of a multiply sampled tumour. Finally,
whilst there is significant intra-tumoral variation, it is less
than inter-tumoral variation and therefore the former should
not be a limitation to the possible usefulness of this techni-
que as an independent prognostic indicator.
The authors gratefully acknowledge the technical support received
from the flow cytometric facilities of the Gray Laboratory and the
Paterson Institute; the histopathological assessment of the tumours
by Drs J.M. Pearson and N.Y. Haboubi and discussions with Drs J.
Hendry and E. Anderson.
This project has been jointly funded by the Christie Hospital NHS
Trust Endowment fund and the Cancer Research Campaign.
References
ALAMA, A., MERLO, F., CHIARA, S., MUTTINI, M.P., GUIDO, T.,
NICOLO, G., CONTE, P.F. & RAGNI, N. (1992). Prediction of
survival by thymidine labelling index in patients with resistant
ovarian cancer. Eur. J. Cancer, 28A, 1079-1080.
BEGG, A.C., HOFLAND, I., MOONEN, L., BARTELINK, H., SCHRAUB,
S. & BONTEMPS, P. (1990). The predictive value of cell kinetic
measurements in a European trial of accelerated fractionation in
advanced head and neck tumours: an interim report. In. J. Rad.
Oncol. Biol. Phys., 19, 1449-1453.
BEGG, A.C., MOONEN, L., HOFLAND, I., DESSING, M. &
BARTELINK, H. (1988). Human tumour cell kinetics using a
monoclonal antibody against iododeoxyuridine: intra-tumoural
sampling variations. Radiother. Oncol., 11, 337-347.
BEGG, A.C., MCNALLY, N.J., SHRIEVE, D.C. & KARCHER, H. (1985).
A method to measure the duration of DNA synthesis and the
Potential Doubling Time form a single sample. Cytometry, 6,
620-626.
BENNETT, M.H., WILSON, G.D., DISCHE, S., SAUNDERS, M.I., MAR-
TINDALE, C.A., ROBINSON, B.M., O'HALLORAN, LESLIE, M.D. &
LAING, J.H.E. (1992). Tumour proliferation assessed by combined
histological and flow cytometric analysis: implications for therapy
in squamous cell carcinoma in the head and neck. Br. J. Cancer,
65, 870-878.
DAVIDSON, S.E., WEST, C.M.L. & HUNTER, R.D. (1992). Lack of
association between in vitro clonogenic growth of human cervical
carcinoma and tumour stage, differentiation, patient age, host cell
infiltration or patient survival. Int. J. Cancer, 50, 10-14.
DEXTER, D.L., SPREMULLI, E.N., FLIGIEL, Z., BARBOSA, J.A.,
VOGEL, R., VAN VOORHEES, A. & CALABRESI, P. (1981).
Heterogeneity of cancer cells from a single human colon car-
cinoma. Am. J. Med., 71, 949-956.
DISCHE, S. & SAUNDERS, M.I. (1989). Continuous, hyperfractionated
accelerated radiotherapy (CHART). Br. J. Cancer, 59,
325-326.
DISCHE, S., SAUNDERS, M.I., BENNETT, M.H., WILSON, G.D. &
MCNALLY, N. (1989). Cell proliferation and differentition in
squamous cancer. Radioth. Oncol., 15, 19-23.
GOLD, D.V., SHOCHAT, D., PRIMUS, F.J., DEXTER, D.L.,
CALABRESI, P. & GOLDENBERG, D.M. (1983). Differential exp-
ressions of tumour-associated antigens in human colon car-
cinomas xenografted into nude mice. J. Natl Cancer Inst., 71,
117-124.
GOSLIN, R., O'BRIEN, M.J., STEELE, G., MAYER, R., WILSON, R.,
CORSON, J.J. & ZAMCHECK, N. (1981). Correlation of plasma
CEA and CEA tissue staining in poorly differentiated colorectal
cancer. Am. J. Med., 71, 246-253.
HIDDEMANN, W., VON BASSEWITZ, D.B., KLEINIMEIER, H.-J.,
SCHULTE-BROCHTERBECK, E., HAUSS, J. & LINGEMANN, B.
(1986). DNA stemline heterogeneity in colorectal cancer. Cancer,
58, 258-263.
HOSHINO, T., NAGASHIMA, T., MOROVIC, J., LEVIN, E.M., LEVIN, J.
& RUPPS, S.M. (1985). Cell kinetic studies of in situ brain tumours
with bromodeoxyuridine. Cytometry, 6, 627-632.
JONES, D.J., MOORE, M. & SCHOFIELD, P.F. (1988). Prognostic
significance of DNA ploidy in colorectal cancer: a prospective
flow cytometric study. Br. J. Surg., 75, 28-33.
JONES, D.J., ZALOUDIK, J., JAMES, R.D., HABOUBI, N.Y., MOORE,
M. & SCHOFIELD, P.F. (1989). Predicting local recurrence of
carcinoma of the rectum after preoperative radiotherapy and
surgery. Br. J. Surg., 76, 1172-1175.
KIMBALL, P.M. & BRATTAIN, M.G. (1980). Isolation of a cellular
subpopulation from a human colonic carcinoma cell line. Cancer
Res., 40, 1574-1579.
KOHA, M., CASPERSSON, T.O., WIKSTROM, B. & BRISMAR, B.
(1990). Heterogeneity of DNA distribution pattern in colorectal
carcinoma. A microspectrophotometric study of fine needle
aspirates. Anal. Quant. Cytol. Histol., 12, 348-351.
KOURI, M., PYRHONEN, S., MECKLIN, J.P., JARVINEN, H.,
LAASONEN, A., FRANSSILA, K. & NORDLING, S. (1990). The
prognostic value of DNA ploidy in colorectal carcinoma: a pro-
spective study. Br. J. Cancer, 62, 976-981.
LAURIE, J.A., MOERTEL, C.G., FLEMING, T.R., WIEAND, H.S.,
LEIGH, J.E. & RUBIN, J. (1989). Surgical adjuvant therapy of
large bowel carcinoma: an evaluation of levamisole and the com-
bination of levamisole and fluorouracil. J. Clin. Oncol., 7,
1447-1456.
LEIBOWITZ, A., STINSON, J.C., MCCOMBS, W.B., McCOY, C.E.,
MAZUR, K.C. & MABRY, N.D. (1976). Classification of human
colorectal adenocarcinoma cell lines. Cancer Res., 36,
4562-4569.
LINDMARK, G., GLIMELIUS, B., PAHLMAN, L. & ENBLAD, P.
(1991). Heterogeneity in ploidy and S phase fraction in colorectal
adenocarcinomas. Int. J. Colorectal Dis., 6, 115-120.506 M.S. WILSON et al.
METZGER, U. (1991). Adjuvant therapy for colorectal cancer. World
J. Surg., 15, 576-582.
O'BRIEN, M.J., ZAMCHECK, N., BURKE, B., KIRKHAM, S.E.,
SARAVAIS, C.A. & GOTTLIEB, L.S. (1981). Immunocytochemical
localisation of carcinoembryonic antigen in benign and malignant
colorectal tissue: assessment of diagnostic value. Am. J. Clin.
Pathol., 75, 283-290.
QUIRKE, P., DIXON, M.F., CLAYDEN, A.D., DURDEY, P., DYSON,
J.E.D., WILLIAMS, N.S. & BIRD, C.C. (1987). Prognostic
significance of DNA aneuploidy and cell proliferation in rectal
adenocarcinomas. J. Pathol., 151, 285-291.
REW, D., WILSON, G., TAYLOR, I. & WEAVER, P. (1991). Measure-
ment of in vivo proliferation in human colorectal tumours. Br. J.
Surg., 78,- 60-66.
REW, D.A., CAMPBELL, I.D., TAYLOR, I. & WILSON, G.D. (1992).
Proliferation indices of invasive breast carcinomas after in vivo
5-bromo-2'deoxyuridine labelling: a flow cytometric study of 75
tumours. Br. J. Surg., 79, 335.
RICCARDI, A., GIORDANO, M., DANOVA, M., GIRINO, M., BRUG-
NATELLI, S., UCCI, G. & MAZZINI, G. (1991). Cell kinetics with in
vivo bromodeoxyuridine and flow cytometry: clinical significance
in acute non-lymphoblastic leukemia. Eur. J. Cancer, 27,
882-887.
ROGNUM, T.O., THOROUD, E., ELGJO, K., BRANDTZAEG, P.,
ORJASAETER, H. & NYGAARD, K. (1982). Large bowel car-
cinomas with different ploidy, related to secretory component,
IgA- and CEA in epithelium and plasma. Br. J. Cancer, 45,
921-934.
SCOTT, N.A., GRANDE, J.P., WEILAND, L.H., PEMBERTON, J.H.,
BEART, R.W. JR, & LIEBER, M.M. (1987). Flow cytometric pat-
terns from colorectal cancers - how reproducible are they? Mayo.
Clin. Proc., 62, 331-337.
SHEPHERD, N.A., RICHMAN, P.I. & ENGLAND, J. (1988). Ki67
derived proliferative activity in colorectal adenocarcinoma with
prognostic correlations. J. Pathol., 155, 213-219.
SIRACKY, J. (1979). An approach to the problem of heterogeneity of
human tumour cell populations. Br. J. Cancer, 39, 570-577.
STEEL, G.G. (1977). Growth Kinetics of Tumours. Oxford University
Press: London.
TROPE, C. & HAKANSSON, L. (1975). Heterogeneity of human
adenocarcinomas of the colon and the stomach as regards sen-
sitivity to cytostatic drugs. Neoplasma, 22, 423-430.
VAN OOSTRUM, I.E.A., ROZEMULLER, E., KNOL, R.F.G., ERKENS-
SCHULZE, S. & RUTGERS, D.H. (1990). Cell proliferation kinetics
of six xenografted human cervix carcinomas: comparison of
autoradiography and bromodeoxyuridine labelling methods. Cell
Tiss. Kinet., 23, 523-544.
WERSTO, R.P., LIBLIT, R.L., DEITCH, D. & KOSS, L.G. (1991).
Variability in DNA measurements in multiple tumour samples of
human colonic carcinoma. Cancer, 67, 106-115.
WILSON, G.D. (1991). Assessment of human tumour proliferation
using bromodeoxyuridine-current status. Acta Oncol., 8,
903-910.
WILSON, G.D. & MCNALLY, N.J. (1991). Measurement of cell pro-
liferation using bromodeoxyuridine. In Cell Proliferation in
Clinical Diagnosis. Hall, P.A., Levison, D.A. & Wright, N.A.
(eds) London, Springer-Verlag, 113-139.
WILSON, G.D., MCNALLY, N.J., DISCHE, S., SAUNDERS, M.I., DES
ROCHERS, C., LEWIS, A.A. & BENNETT, M.H. (1988). Measure-
ment of cell kinetics in human tumours in vivo using BUdR
incorporation and flow cytometry. Br. J. Cancer, 58,
423-431.
WILSON, G.D., MCNALLY, N.J., DUNPHY, E., KARCHER, H. &
PFRAGNER, R. (1985). The labelling index of human and mouse
tumours assessed by bromodeoxyuridine staining in vitro and in
vivo and flow cytometry. Cytometry, 6, 641-647.
WILSON, M.S., WEST, C.M.L., WILSON, G.D., ROBERTS, S.A., JAMES,
R.D. & SCHOFIELD, P.F. (1993). An assessment of the reliability
and reproducibility of measurement of potential doubling times
(Tpo0) in human colorectal tumours. Br. J. Cancer, 67,
754-759.
ZAMCHECK, N., DOOS, W.G., PRUDENTE, R., LURIE, B.B. & GOTT-
LIEB, L.S. (1975). Prognostic factors in colon carcinoma. Hum.
Pathol., 6, 31-45.